Bristol-Myers Squibb Company expected to report Q3 2010 results on October 21, 2010. This event was calculated by Capital IQ (Created on July 24, 2010).

Bristol-Myers Squibb Company Presents at Market Research and Product Forecasting Summit, Jul-27-2010 02:30 PM. Venue: Doubletree Hotel, 237 South Broad Street, Philadelphia, PA 19107, United States. Speakers: Michael Devinoff, Executive Director, Forecasting and Epidemiology.

Bristol-Myers Squibb Company announced unaudited consolidated second quarter and six months ended June 30, 2010. For the second quarter, on GAAP basis, the company reported net sales of $4.8 billion, an increase of 2% compared to $4.67 billion in the same period in 2009. Earnings from continuing operations before income taxes were $1,592 million compared to $1,522 million a year ago. Net earnings continuing operations was $1,268 million compared to $1,169 million a year ago. Net earnings continuing operations attributable to the company was $927 million or $0.53 per diluted share compared to $880 million or $0.54 per diluted share a year ago. On non- GAAP basis, the company reported net sales of $4,768 million compared to $4,665 million a year ago. Earnings from continuing operations before income taxes was $1,686 million compared to $1,650 million a year ago. Net earnings continuing operations was $341 million compared to $289 million a year ago. Net earnings continuing operations attributable to the company was $944 million or $0.44 per diluted share compared to $966 million or $0.48 per diluted share for the same period a year ago. For the six months, on GAAP basis, the company reported net sales of $9,575 million compared to $8,987 million a year ago. Earnings from continuing operations before income taxes were $3,044 million compared to $2,717 million a year ago. Net earnings continuing operations was $2,369 million compared to $2,089 million a year ago. Net earnings continuing operations attributable to the company was $1,670 million or $0.96 per diluted share compared to $1,529 million or $0.77 per diluted share for the same period a year ago. On non-GAAP basic, the company reported net sales of $9,575 million compared to $8,987 million a year ago. Earnings from continuing operations before income taxes were $3,448 million compared to $3,118 million a year ago. Net earnings continuing operations was $2,610 million compared to $2,355 million a year ago. Net earnings continuing operations was $1,911 million or $1.10 per diluted share compared to $1,795 million or $0.90 per diluted share for the same period a year ago. The company reported impairment and loss on sale of manufacturing operations of $15 million for the second quarter ended June 30, 2010. The company reaffirms its 2010 GAAP EPS guidance range of $1.84 to $1.94 per share and its non-GAAP guidance range of $2.10 to $2.20 per share. Key 2010 guidance assumptions include: mid-single digit revenue growth; full-year gross margin being consistent with last year; advertising and promotion expense decrease in the high-single digit range; marketing, sales and administrative expenses remaining flat; research and development expense growth in the mid- to high-single-digit range; and an effective tax rate of between 23% and 24%. The company reaffirms its minimum non-GAAP EPS guidance of $1.95 for 2013. This 2013 guidance assumes strong underlying revenue trends for certain key products, timely regulatory approval of and significant contributions from pipeline products, continued and additional productivity savings, exclusivity for ABILIFY(R) for the term of the current agreement with Otsuka Pharmaceutical Co. Ltd., and that the negative impact of U.S. health care reform and European government-mandated cost containment measures is not substantially different from current expectations.